This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Overexpression of PVR and PD-L1 and Its Association With Prognosis in Surgically Resected Squamous Cell Lung Carcinoma
Hye Ryun Kim
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea;
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Targeting T-Cell Immunoreceptor with Ig and ITIM domain-poliovirus receptor (PVR) pathway is a potential therapeutic strategy in lung cancer. We analyzed the expression of PVR and programmed death ligand-1 (PD-L1) in surgically resected squamous cell lung carcinoma (SQCC) and determined its prognostic significance.
Methods: We collected archival surgical specimens of 259 patients with SQCC at Yonsei Cancer Center (1998–2020). Analysis of variance was used to analyze the correlations between PVR and PD-L1 expression and patient characteristics. Kaplan–Meier curves were used to estimate recurrence-free survival (RFS) and overall survival (OS).
Results: Most patients were male (93%); the majority were diagnosed with stage 1 (47%), followed by stage 2 (29%) and stage 3 (21%). Overexpression of PVR resulted in a significantly shorter median RFS and OS (P = 0.01). PD-L1 expression was not significant in terms of prognosis. Patients were subdivided into four groups based on low and high PVR and PD-L1 expression. Those expressing high levels of PVR and PD-L1 had the shortest RFS (P = 0.03).
Conclusions: PVR overexpression is associated with a poor prognosis in surgically resected SQCC. Inhibition of PVR as well as PD-L1 may help overcome the lack of response to immune checkpoint monotherapy.
Keywords
domain-poliovirus receptor (PVR), squamous cell lung carcinoma (SQCC), recurrence-free survival (RFS)
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 04 Jan, 2021
No community comments so far
Editorial decision: Major revision
On 03 Feb, 2021
Review #2 received
Received 24 Jan, 2021
Review #3 received
Received 24 Jan, 2021
Review #4 received
Received 24 Jan, 2021
Review #1 received
Received 24 Jan, 2021
Reviewer #2 agreed
On 17 Jan, 2021
Reviewer #5 agreed
On 17 Jan, 2021
Reviewer #6 agreed
On 17 Jan, 2021
Reviewer #7 agreed
On 17 Jan, 2021
Reviewer #4 agreed
On 17 Jan, 2021
Reviewer #3 agreed
On 17 Jan, 2021
Reviewer #1 agreed
On 17 Jan, 2021
Reviewers invited
Invitations sent on 07 Jan, 2021
Editor assigned
On 30 Dec, 2020
Editor invited
On 29 Dec, 2020
Submission checks complete
On 29 Dec, 2020
First submitted
On 24 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
Learn more about our company.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Overexpression of PVR and PD-L1 and Its Association With Prognosis in Surgically Resected Squamous Cell Lung Carcinoma
Hye Ryun Kim
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea;
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 04 Jan, 2021
No community comments so far
Editorial decision: Major revision
On 03 Feb, 2021
Review #2 received
Received 24 Jan, 2021
Review #3 received
Received 24 Jan, 2021
Review #4 received
Received 24 Jan, 2021
Review #1 received
Received 24 Jan, 2021
Reviewer #2 agreed
On 17 Jan, 2021
Reviewer #5 agreed
On 17 Jan, 2021
Reviewer #6 agreed
On 17 Jan, 2021
Reviewer #7 agreed
On 17 Jan, 2021
Reviewer #4 agreed
On 17 Jan, 2021
Reviewer #3 agreed
On 17 Jan, 2021
Reviewer #1 agreed
On 17 Jan, 2021
Reviewers invited
Invitations sent on 07 Jan, 2021
Editor assigned
On 30 Dec, 2020
Editor invited
On 29 Dec, 2020
Submission checks complete
On 29 Dec, 2020
First submitted
On 24 Dec, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Oncology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Targeting T-Cell Immunoreceptor with Ig and ITIM domain-poliovirus receptor (PVR) pathway is a potential therapeutic strategy in lung cancer. We analyzed the expression of PVR and programmed death ligand-1 (PD-L1) in surgically resected squamous cell lung carcinoma (SQCC) and determined its prognostic significance.
Methods: We collected archival surgical specimens of 259 patients with SQCC at Yonsei Cancer Center (1998–2020). Analysis of variance was used to analyze the correlations between PVR and PD-L1 expression and patient characteristics. Kaplan–Meier curves were used to estimate recurrence-free survival (RFS) and overall survival (OS).
Results: Most patients were male (93%); the majority were diagnosed with stage 1 (47%), followed by stage 2 (29%) and stage 3 (21%). Overexpression of PVR resulted in a significantly shorter median RFS and OS (P = 0.01). PD-L1 expression was not significant in terms of prognosis. Patients were subdivided into four groups based on low and high PVR and PD-L1 expression. Those expressing high levels of PVR and PD-L1 had the shortest RFS (P = 0.03).
Conclusions: PVR overexpression is associated with a poor prognosis in surgically resected SQCC. Inhibition of PVR as well as PD-L1 may help overcome the lack of response to immune checkpoint monotherapy.
Figure 1
Figure 2
Figure 3
Figure 4